Regulus Therapeutics reported $20.01M in Cash and Equivalent for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Alnylam Pharmaceuticals ALNY:US USD 1.07B 497.67M
Astrazeneca AZN:US USD 4.46B 359M
AstraZeneca AZN:LN USD 4.46B 359M
Biogen BIIB:US USD 3.68B 1.03B
Celldex Therapeutics CLDX:US USD 18.58M 9.82M
Gilead Sciences GILD:US USD 6.94B 2.2B
GlaxoSmithKline GSK:LN GBP 3.61B 2.86B
Intercept Pharmaceuticals ICPT:US USD 113.2M 55.18M
Intrexon XON:US USD 9.07M 34.78M
Lexicon Pharmaceuticals LXRX:US USD 18.83M 2.62M
Ligand Pharmaceuticals LGND:US USD 121.41M 116.13M
Omeros OMER:US USD 145.53M 131.4M
Regulus Therapeutics RGLS:US USD 20.01M 15.1M
Sangamo Biosciences SGMO:US USD 94.57M 23.14M
Spectrum Pharmaceuticals SPPI:US USD 56.26M 30.74M
Takeda 4502:JP JPY 798.14B 152.15B
Vital Therapies VTL:US USD 72.77M 15.31M
YTE INCY:US USD 2.69B 255.24M